CTRI/2012/02/002440招募中3 期
A Control- Labeled, Prospective, Randomized, Parallel Group, Multicentric, Phase III Clinical trial to Evaluate Efficacy and Safety of a FDC of Lornoxicam 16mg SR + Thiocolchicoside 16mg SR Tablet OD Compared with Thiocolchicoside 8mg Capsule BID in Patients Suffering pain associated with Skeletal Muscular Spasm of any etiology
Inventia Healthcare Pvt Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Non specific skeletal muscular spasm, with an acute episode.
- •Recent onset ( <48 hours) defined by average pain and local immobility within the last 24 hours equal or more than grade 4 on the Visual Analogue Scale (VAS)
- •Willing to give written informed consent.
排除标准
- •Acute pain due to vertebral collapse or of no mechanical origin (suspected by history taking and physical examination), such as neoplasm, infection or inflammatory disorders.
- •Low back pain of diagnosis category 3 (low back pain radiating beyond the knee, with no neurologic signs) or 4 (low back pain radiating to a precise and entire leg dermatome, with or without neurologic signs), as defined by the International Paris Task Force on Back Pain ( Annexure â??V)
- •History of inflammatory arthritis of large joints.
- •History of seizure disorders.
- •History of malignant tumor.
- •Treatment with steroidal agents (including aspirin) during the two days prior to prospective inclusion, prolonged used of corticosteroids.
- •Treatment with NSAIDs or muscle relaxant or opioid analgesics within 3 days of admission,
- •Psychiatric or mental diseases.
- •Immune Compromised HIV.
- •Inclusion in another study in the past six months or previous inclusion in this study,
- •History of alcohol, drugs or narcotics abuse.
- •Recent history of violent trauma.
- •Constant progressive, non mechanical pain (no relief with bed rest).
- •Thoracic pain.
- •Patient systemically unwell.
- •Unexplained weight loss.
- •Widespread neurological symptoms (including Cauda equine syndrome).
- •Structural deformity.
- •Clinical significant renal dysfunction defined by Creatinine > 1.5 mg/dl
- •Clinically significant hepatic dysfunction defined by:
- •Total Bilirubin > 2 mg/dl
- •SGOT (AST) > 1.5 IU/L
- •SGPT (ALT) > 1.5 IU/L
- •Patients who have received other therapy (physiotherapy, physical manipulations, invasive intervention, acupuncture therapy.) within the last 48 hours.
- •Pregnancy, breast feeding or women of childbearing potential not using efficient contraception.
- •Known or suspected hypersensitivity to Thiocolchicoside and Lornoxicam.
研究者
相似试验
已完成
3 期
Control- Labeled, Prospective, Randomized, Parallel group, Multicentric, Phase III Clinical Trial to Evaluate Efficacy and Safety of Eperisone HCl SR 150mg OD Capsule compared with Eperisone HCl 50mg Tablet T.I.D in patients suffering from Acute Musculoskeletal Spasm associated with Low Back Pain.CTRI/2010/091/001138Inventia Health Care Pvt Ltd200
已完成
3 期
A Control- Labeled, Prospective, Randomized, Parallel Group, Multicentric, Phase III Clinical trial to evaluate Efficacy and Safety of a FDC of Lornoxicam 16mg SR + Thiocolchicoside 16mg SR Tablet OD Compared with FDC Lornoxicam 8mg + Thiocolchicoside 8mg Capsule BID in Patients Suffering from skeletal Muscular spasm of any etiology.CTRI/2011/091/000010Alembic Ltd200
已完成
3 期
Controlled Labeled, Randomized Prospective, Multicentric Parallel Group, Phase-III Clinical Trial to Compare Efficacy and Safety for FDC of Eperisone150mg SR and Diclofenac 100mg SR capsule OD with Eperisone 50 mg EC Tablet T.I.D in Subjects suffering with Acute Musculoskeletal Spasm Associated With Low Backache.CTRI/2010/091/001154Inventia Health Care Pvt. Ltd.200
已完成
4 期
To assess safety, efficacy and tolerability of Formoterol Budesonide nebulised formulationin comparison with Formoterol Budesonide pressurized meter dose formulation inCOPD patientsCTRI/2012/11/003087Cipla Ltd112
尚未招募
Unknown
A Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Electroacupuncture and Its Cotreatment with Electronic Moxibustion for Dry eye syndromeKCT0009622aju Dongshin University Korean Medicine Hospital45